Results of a Randomized placebo-controlled study of memory training for mildly impaired Alzheimer's disease patients

被引:69
|
作者
Cahn-Weiner, DA
Malloy, PF
Rebok, GW
Ott, BR
机构
[1] Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI USA
[2] Mem Hosp Rhode Isl, Pawtucket, RI USA
[3] Butler Hosp, Providence, RI 02906 USA
[4] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[5] Brown Med Sch, Dept Clin Neurosci, Providence, RI USA
来源
APPLIED NEUROPSYCHOLOGY | 2003年 / 10卷 / 04期
关键词
memory training; Alzheimer's Disease; randomized placebo-controlled;
D O I
10.1207/s15324826an1004_3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The efficacy of a memory-training program to improve word-list recall and recognition was evaluated in 34 patients with probable Alzheimer's disease (AD). The patients, who were all taking donepezil throughout the 6-week intervention, were randomly assigned to a cognitive intervention group or a control group. The Control group received didactic presentations but no formal memory training. Patients were assessed on neuropsychological tests before the 6-week training program, immediately after the training, and 8 weeks after completion of the training. Caregivers, who were blind to group assignment, completed activities of daily living (ADLs) and everyday memory questionnaires at all three timepoints. No significant main effects of group (training vs. control) or time were observed on any outcome measures, nor were any significant interactions found. In terms of "process" measures during the 6-week training program, the patients demonstrated modest improvement on recall and recognition of test material presented during the training sessions. These results suggest that although modest gains in learning and memory may be evident in AD patients who are taught specific strategies, the benefits do not generalize to other measures of neuropsychological functioning after a brief intervention.
引用
收藏
页码:215 / 223
页数:9
相关论文
共 50 条
  • [41] Estrogen for Alzheimer's disease in women - Randomized, double-blind, placebo-controlled trial
    Henderson, VW
    Paganini-Hill, A
    Miller, BL
    Elble, RJ
    Reyes, PF
    Shoupe, D
    McCleary, CA
    Klein, RA
    Hake, AM
    Farlow, MR
    NEUROLOGY, 2000, 54 (02) : 295 - 301
  • [42] Selegiline in the treatment of Alzheimer's disease:: a long-term randomized placebo-controlled trial
    Filip, V
    Kolibás, E
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 1999, 24 (03): : 234 - 243
  • [43] Ethical issues in placebo-controlled trials in Alzheimer's disease
    Goldney, RD
    Stoffell, BF
    MEDICAL JOURNAL OF AUSTRALIA, 2000, 173 (03) : 147 - 148
  • [44] A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease
    Brody, Mark
    Liu, Enchi
    Di, Jianing
    Lu, Ming
    Margolin, Richard A.
    Werth, John L.
    Booth, Kevin
    Shadman, Anna
    Brashear, H. Robert
    Novak, Gerald
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 54 (04) : 1509 - 1519
  • [45] Working memory training in young children with ADHD: a randomized placebo-controlled trial
    van Dongen-Boomsma, Martine
    Vollebregt, Madelon A.
    Buitelaar, Jan K.
    Slaats-Willemse, Dorine
    JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY, 2014, 55 (08) : 886 - 896
  • [46] Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial
    Dubois, Bruno
    Lopez-Arrieta, Jesus
    Lipschitz, Stanley
    Triantafyllos, Doskas
    Spiru, Luiza
    Moroz, Svitlana
    Venger, Olena
    Vermersch, Patrick
    Moussy, Alain
    Mansfield, Colin D. D.
    Hermine, Olivier
    Tsolaki, Magda
    ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)
  • [47] Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
    Bruno Dubois
    Jesús López-Arrieta
    Stanley Lipschitz
    Triantafyllos Doskas
    Luiza Spiru
    Svitlana Moroz
    Olena Venger
    Patrick Vermersch
    Alain Moussy
    Colin D. Mansfield
    Olivier Hermine
    Magda Tsolaki
    Alzheimer's Research & Therapy, 15
  • [48] Role of zonisamide in advanced Parkinson's disease: a randomized placebo-controlled study
    Essam, Mohamed
    Hamid, Eman
    Abushady, Eman
    El-Balkimy, Mahmoud
    Antonini, Angelo
    Shalash, Ali
    NEUROLOGICAL SCIENCES, 2024, 45 (04) : 1725 - 1734
  • [49] Role of zonisamide in advanced Parkinson’s disease: a randomized placebo-controlled study
    Mohamed Essam
    Eman Hamid
    Eman Abushady
    Mahmoud El-Balkimy
    Angelo Antonini
    Ali Shalash
    Neurological Sciences, 2024, 45 : 1725 - 1734
  • [50] Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial
    Akhondzadeh, S.
    Shafiee-Sabet, M.
    Harirchian, M. H.
    Togha, M.
    Cheraghmakani, H.
    Razeghi, S.
    Hejazi, S. Sh
    Yousefi, M. H.
    Alimardani, R.
    Jamshidi, A.
    Zare, F.
    Moradi, A.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (05) : 581 - 588